MX2010011845A - Agonistas del receptor y2 y/o y4 de larga accion. - Google Patents

Agonistas del receptor y2 y/o y4 de larga accion.

Info

Publication number
MX2010011845A
MX2010011845A MX2010011845A MX2010011845A MX2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A MX 2010011845 A MX2010011845 A MX 2010011845A
Authority
MX
Mexico
Prior art keywords
ethoxy
seq
carboxy
acid
acetyl
Prior art date
Application number
MX2010011845A
Other languages
English (en)
Spanish (es)
Inventor
Soeren Oestergaard
Sanne Moeller Knudsen
Jane Spetzler
Rasmus Joergensen
Jacob Kofoed
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2010011845A publication Critical patent/MX2010011845A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010011845A 2008-05-16 2009-05-18 Agonistas del receptor y2 y/o y4 de larga accion. MX2010011845A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP09154461 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (1)

Publication Number Publication Date
MX2010011845A true MX2010011845A (es) 2010-11-22

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011845A MX2010011845A (es) 2008-05-16 2009-05-18 Agonistas del receptor y2 y/o y4 de larga accion.

Country Status (12)

Country Link
US (1) US20110275559A1 (enExample)
EP (1) EP2279204A1 (enExample)
JP (1) JP2011520847A (enExample)
KR (1) KR20110017874A (enExample)
CN (1) CN102027007A (enExample)
AU (1) AU2009248041B2 (enExample)
BR (1) BRPI0912615A2 (enExample)
CA (1) CA2723855A1 (enExample)
IL (1) IL208836A0 (enExample)
MX (1) MX2010011845A (enExample)
RU (1) RU2504550C2 (enExample)
WO (1) WO2009138511A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US8927687B2 (en) 2010-07-09 2015-01-06 Amylin Pharmaceuticals, Llc Microcrystalline Y receptor agonists
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
PT3068421T (pt) * 2013-11-15 2019-07-11 Novo Nordisk As Compostos de pyy eletivo e usos dos mesmos
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
EP3068795B1 (en) * 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
EP3094391B1 (en) 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
CA2949535C (en) * 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
IL297368A (en) * 2020-04-17 2022-12-01 I2O Therapeutics Inc Long-acting peptide tyrosine kinase (pyy) analogs and methods of use
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
BR122019021416A2 (enExample) * 2003-09-19 2019-12-21
US8603969B2 (en) * 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP2060266B1 (en) * 2004-03-17 2011-08-10 7TM Pharma A/S Y4 selective receptor agonist PP2-36 for therapeutic interventions
CA2572770A1 (en) * 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽

Also Published As

Publication number Publication date
WO2009138511A1 (en) 2009-11-19
BRPI0912615A2 (pt) 2016-01-26
KR20110017874A (ko) 2011-02-22
AU2009248041B2 (en) 2013-10-03
JP2011520847A (ja) 2011-07-21
US20110275559A1 (en) 2011-11-10
EP2279204A1 (en) 2011-02-02
AU2009248041A1 (en) 2009-11-19
CA2723855A1 (en) 2009-11-19
RU2504550C2 (ru) 2014-01-20
IL208836A0 (en) 2011-01-31
CN102027007A (zh) 2011-04-20
RU2010149474A (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
MX2010011845A (es) Agonistas del receptor y2 y/o y4 de larga accion.
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
EP2190873B1 (en) Truncated glp-1 derivatives and their therapeutical use
AU2010203063B2 (en) Albumin-binding derivatives of therapeutic peptides
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
US20130040877A1 (en) Long-acting y2 receptor agonists
EP2190460A1 (en) Peptides derivatized with a-b-c-d- and their therapeutical use
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal